Actividad Investigadora
Biopsia líquida para el diagnóstico molecular de pacientes con Linfoma B agresivo incluidos en ensayo clínico
Datos básicos
- Código:
- PI19/00041
- Dotación:
- 129.470,00 €
- Año Inicial:
- 2020
- Año final:
- 2023
Objetivos del proyecto
1) Genetic characterization by NGS of a selection of aggressive large B cell lymphoma cases using ctDNA methodology and exome NGS from tumor samples derived from clinical trials and retrospective cohorts. a) Characterization of clonal evolution patterns and its potential implications for targeted therapy using ctDNA analysis and FFPE based whole exome NGS genotyping in serial samples from LR-ESHAP trial. b) Characterization of a cohort of non-GCB DLBCL patient samples (ctDNA) included in two clinical trials from GELTAMO group (GEL-RCOMP 2013 (Nº EudraCT: 2013-001065-17), IBDCL-GELTAMO 2015 (Nº EudraCT:2015-005390-21)). IBDCL 2015 is a multicenter phase II clinical trial for the evaluation of eficacy and safety of Ibrutinib (btK inhibitor) in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by ibrutinib maintenance in patients with relapsed/refractory non-GCB type DLBCL. c) Description of the mutational profile of the whole exome of 45 plasmablastic lymphoma cases. 2) Profiling of T cell repertoires in the tumor samples by TCR NGS and immunophenotyping. Correlation of mutational architectures with defective T cell response patterns and immune checkpoint expression. 3) Functional characterization of PRDM1/Blimp1 inactivation in B cell lymphoma, and validation in LPL and plasmablastic lymphoma samples.
Unidades de investigación
Documentos
- No hay documentos
Participantes
Financiadores
